Autolus

London, United Kingdom Founded: 2015 • Age: 11 yrs
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
Request Access

About Autolus

Autolus is a company based in London (United Kingdom) founded in 2015.. Autolus has raised $181.37 million across 5 funding rounds from investors including BioNTech, Blackstone and Syncona. The company has 647 employees as of December 31, 2024. Autolus operates in a competitive market with competitors including Moderna, Senti Biosciences, Horizon Therapeutics, Forge Biologics and argenx, among others.

  • Headquarter London, United Kingdom
  • Employees 647 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Autolus Therapeutics Plc Sponsored Adr
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $10.12 M
    496.25
    as on Dec 31, 2024
  • Net Profit
    $-220.75 M
    -5.94
    as on Dec 31, 2024
  • EBITDA
    $-213.46 M
    -13.27
    as on Dec 31, 2024
  • Total Equity Funding
    $181.37 M (USD)

    in 5 rounds

  • Latest Funding Round
    $200 M (USD), Post-IPO

    Feb 08, 2024

  • Investors
    BioNTech

    & 5 more

  • Employee Count
    647

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Autolus

Autolus is a publicly listed company on the NASDAQ with ticker symbol AUTL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: AUTL . Sector: Health technology · USA
People of Autolus
Headcount 500-1000
Employee Profiles 133
Employee Profiles
People
William Hall
Lead Technical Specialist, MSAT
People
Martin Pule
SVP, Founder & Chief Scientific Officer
People
Christopher Vann
SVP & Chief Operating Officer
People
Yousef Farag
Research Scientist

Unlock access to complete

Funding Insights of Autolus

Autolus has successfully raised a total of $181.37M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Post-IPO — $200.0M
  • First Round

    (22 Jan 2015)

  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2024 Amount Post-IPO - Autolus Valuation

investors

Nov, 2021 Amount Post-IPO - Autolus Valuation

investors

Sep, 2017 Amount Series C - Autolus Valuation Syncona
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Autolus

Autolus has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include BioNTech, Blackstone and Syncona. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Diversified investment management is provided across multiple asset classes.
Founded Year Domain Location
PE firm investing in the US
Founded Year Domain Location
Healthcare investments are managed via private equity by Syncona.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Autolus

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Autolus

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Autolus Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Autolus

Autolus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Senti Biosciences, Horizon Therapeutics, Forge Biologics and argenx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Cell-based therapies for cancer treatment are developed.
domain founded_year HQ Location
Developer of drugs for treating rare and autoimmune diseases
domain founded_year HQ Location
Gene therapies for rare diseases are developed to treat patients.
domain founded_year HQ Location
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
domain founded_year HQ Location
Provider of cell therapies to treat cancer and hematologic conditions
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Autolus

Frequently Asked Questions about Autolus

When was Autolus founded?

Autolus was founded in 2015.

Where is Autolus located?

Autolus is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Who is the current CEO of Autolus?

Christian Martin Itin is the current CEO of Autolus.

Is Autolus a funded company?

Autolus is a funded company, having raised a total of $181.37M across 5 funding rounds to date. The company's 1st funding round was a Series C of $80M, raised on Jan 22, 2015.

How many employees does Autolus have?

As of Dec 31, 2024, the latest employee count at Autolus is 647.

What is the annual revenue of Autolus?

Annual revenue of Autolus is $10.12M as on Dec 31, 2024.

What does Autolus do?

Autolus was founded in 2015 in London, United Kingdom, within the biotechnology sector. Engineered T-cell therapies are developed and commercialized by the company, targeting hematological and solid tumors. A pipeline of CAR T-cell products is advanced using proprietary targets, constructs, and technologies. Emphasis is placed on immunotherapy applications for cancer and auto-immune conditions.

Who are the top competitors of Autolus?

Autolus's top competitors include Moderna, argenx and Forge Biologics.

Is Autolus publicly traded?

Yes, Autolus is publicly traded on NASDAQ under the ticker symbol AUTL.

Who are Autolus's investors?

Autolus has 6 investors. Key investors include BioNTech, Blackstone, Syncona, Arix Bioscience, and Woodford Investment Management.

What is Autolus's ticker symbol?

The ticker symbol of Autolus is AUTL on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available